Aamir Memon, MD
Nephrology · Elgin, ILNPI 1013074442
Payments from drug & device makers
Across 168 payments — averaging $34.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- Amgen$548
- Otsuka America Pharmaceutical, Inc.$483
- Veloxis Pharmaceuticals, Inc.$442
- Mallinckrodt Hospital Products Inc.$361
- Boehringer Ingelheim$276
- plus $3K from 26 others
What the payments were for
- Speaking & faculty fees$2003%
- Food & beverage$5,39492%
- Education$2695%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 34 | $1,212 |
| Amgen(2 entities) | 14 | $548 |
| Otsuka America Pharmaceutical, Inc. | 19 | $483 |
| Veloxis Pharmaceuticals, Inc. | 1 | $442 |
| Mallinckrodt Hospital Products Inc. | 13 | $361 |
| Boehringer Ingelheim | 4 | $276 |
| ANI Pharmaceuticals, Inc. | 3 | $222 |
| OPKO Pharmaceuticals, LLC | 10 | $208 |
| Vifor Pharma, Inc. | 1 | $200 |
| Akebia Therapeutics Inc | 7 | $171 |
| Fresenius USA Marketing, Inc. | 7 | $169 |
| Novartis | 8 | $161 |
| Calliditas Therapeutics US Inc. | 8 | $158 |
| GSK | 2 | $134 |
| Travere Therapeutics, Inc. | 5 | $125 |
| Sanofi-aventis U.S. LLC | 1 | $111 |
| Mallinckrodt Enterprises LLC | 1 | $100 |
| Ardelyx, Inc. | 5 | $99 |
| Biotronik Inc. | 1 | $82 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 3 | $81 |
| Aurinia Pharma U.S., Inc. | 3 | $75 |
| Alnylam Pharmaceuticals Inc. | 3 | $73 |
| Bard Peripheral Vascular, Inc. | 1 | $69 |
| Novo Nordisk | 3 | $57 |
| Bayer | 2 | $55 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $55 |
| Shire North American Group Inc | 2 | $38 |
| Apellis Pharmaceuticals, Inc. | 1 | $24 |
| Daiichi Sankyo Inc. | 1 | $23 |
| Xeris Pharmaceuticals, Inc. | 1 | $19 |
| Cycle Pharmaceuticals Inc | 1 | $18 |
| Strongbridge US Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Envarsus$442
- LOKELMA$351
- JARDIANCE$219
- Veltassa$200
- KRYSTEXXA$125
- Tavneos$121
- BENLYSTA$118
- PURIFIED CORTROPHIN GEL$115
- THYMOGLOBULIN$111
How this compares
$5,863 in reported general payments places this provider in the 80th percentile of 524 nephrology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Thiola EcTiopronin | 12 | $93,837 |
| VelphoroSucroferric Oxyhydroxide | 30 | $88,954 |
| FarxigaDapagliflozin Propanediol | 78 | $65,301 |
| JardianceEmpagliflozin | 74 | $59,355 |
| RayaldeeCalcifediol | 22 | $29,947 |
| LokelmaSodium Zirconium Cyclosilicate | 39 | $27,166 |
| Sevelamer Carbonate | 63 | $15,758 |
| VeltassaPatiromer Calcium Sorbitex | 16 | $14,977 |
| Bumetanide | 120 | $5,541 |
| Cinacalcet Hcl | 24 | $4,417 |
| Calcitriol | 224 | $3,423 |
| Torsemide | 221 | $3,227 |
| Paricalcitol | 22 | $3,133 |
| Potassium Chloride | 96 | $2,854 |
| Losartan Potassium | 330 | $2,807 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Lokelma | $1,212 | $92,467117 claims |
| Fresenius USA Marketing, Inc.Velphoro | $169 | $88,95430 claims |
| Boehringer IngelheimJardiance | $276 | $59,35574 claims |
| OPKO Pharmaceuticals, LLCRayaldee | $208 | $29,94722 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 524 nephrology providers in Illinois.
Other nephrology in Elgin
- Myles WolfChicago$22.4M
- Suneel UdaniHinsdale$6.8M
- Paul CrawfordEvergreen Park$3.1M
- Beatrice ConcepcionChicago$2.6M
- April KennedyChicago$1.8M
- Khaleel SayeedChicago$1.7M
- Woojin James ChonHines$1.1M
- Mohammed AhmedBolingbrook$1.1M
- Tamara IsakovaChicago$763K
- William WhittierChicago$668K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.